Many special molecules called nuclear RNA-binding proteins (RBPs), which occur outside of the nucleus, develop in several brain disorders including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
Unwanted blobs. Dr. James Shorter, associate professor of biochemistry and biophysics at the Perelman School of Medicine at the University of Pennsylvania, said: “The clumps formed by these disease proteins are made of sticky fibrils that damage nerve cells.
“We want to reverse these The formation of clumps and the return of RNA binding proteins to their proper place in the nucleus.”
Normally, nuclear-import receptors (NIRs) bind to specific sequences of amino acids on the RBPs, to shepherd them into the nucleus.
A team led by Shorter, describes in Cell this week what happened when they added NIRs to aggregates made from TDP-43 and FUS proteins, which are connected to these neurodegenerative diseases.
“When we increased the concentration of NIRs, there were three important and surprising outcomes,” said co-first author Lin Guo, PhD, a Target ALS Springboard Fellow.
First, clumps of RBPs dissolved in test-tube experiments. Next, NIRs also dissolved cytoplasmic clumps in cells and functional RBPs were returned to the nucleus.
And finally, when the expression of NIRs was increased in fruitfly models of disease, lifespan was extended and degeneration was reduced.
“All of this biochemistry was highly unanticipated,” said co-first author Henry Wang, an MD/PhD student at Penn. “We didn’t suspect that the NIRs would break up the clumps, return the RBPs to the nucleus, and mitigate neurodegeneration.”
The team was surprised by how rapidly the NIRs could reverse the formation of the FUS and TDP-43 clumps.
The transition from the RBP being dissolved in solution to forming droplet-like structures normally happens in the nucleus as a regular part of RBP function.
However, when RBPs, like FUS and TDP-43, are misplaced in the cytoplasm, these phase changes can become aberrant, setting the RBPs on a destructive path, which can be corrected with NIRs. But, NIR expression or activity likely becomes reduced in disease.
“Given this complexity, we are now working to find a way to increase expression or activity of NIRs in neurons with clumps using protein engineering or small-molecule drugs,” said coauthor Charlotte Fare, a doctoral student in Shorter’s lab.
Collaborators include co-senior author J. Paul Taylor, MD, PhD, an investigator with the Howard Hughes Medical Institute and chair of Cell and Molecular Biology at St. Jude Children’s Research Hospital; Clotilde Lagier-Tourenne, Mass General Hospital; Yuh Min Chook, University of Texas; and Udai Pandey, University of Pittsburgh.
This research was funded by the National Institute of Health (R21NS090205), Target ALS, the ALS Association, and the The Robert Packard Center for ALS Research at Johns Hopkins.